Abstract:Abstract Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide with five-year overall survival rate of about 50%. Analysis of The Cancer Genome Atlas (TCGA) dataset showed that one or more molecules linked to the tumor necrosis factor receptor (TNF)-NF-κB/REL signal pathway are genetically altered in most HNSCC, and experimental studies show this pathway drives expression of pro-proliferative, inflammatory, angiogenic, and therapeutic resistance genes. Such prevalence and effect across diverse genes suggest that the TNF-NF-κB/REL pathway interacts with molecules that are involved in multiple pathways, but their identity and mechanistic relationship to increased NF-κB signaling have not been studied in detail. Towards this hypothesis, we established a stable NF-κB β−lactamase reporter cell line and performed a genome-wide RNAi screening to identify key regulators of NF-κB oncogenic signaling and proliferation. As expected, the screening and validation data confirmed most components of the TNF receptor complex and downstream NF-κB pathway genes, such as IKKs, contribute to TNFα induced NF-κB activation and cell viability. We further identified and validated a novel sets of genes, which unexpectedly co-modulate NF-κB activity, including those related to the G2M cell cycle checkpoint, such as WEE1, PLK1, AURKA, TTK, CDC2, CDC7 and CALM2, as well as components related to kinetochore such as TPR, NDC80, and NUF2. After confirming sustained knockdown of selected mRNAs and proteins using siRNA by 48-72-hours post transfection, their effects on UM-SCC 1 were evaluated by real-time cell impedance assay. Cell index was significantly decreased by NDC80, NUF2, PLK1, or AURKA knockdown as compared to control siRNA knockdown. In addition, TNF-α treatment further decreased cellular density after NUF2, TPR, PLK1, and AURKA knockdown. The targeted drugs such as volasertib (PLK1), alisertib (AURKA), and adavosertib (WEE1) decreased cell density in a dose-dependent manner, while adavosertib and volasertib also attenuated NF-κB signaling. Thus, we demonstrate a novel link between NF-κB signaling with G2M kinases and kinetochore-related molecules to co-modulate tumor cell growth and survival. Integrated genomics and mechanistic studies are currently underway to understand how G2M and kinetochore-related molecules modulate NF-κB activation and their potential for cancer therapeutics. Supported by NIDCD projects ZIA-DC-000016, -73, -74, and the Medical Research Scholars Program (JWJ). Citation Format: Jun W. Jeon, Anthony D. Saleh, Shaleeka Cornelius, Sophie Carlson, Scott Martin, Pinar Ormanoglu, Hui Cheng, Xinping Yang, Chris Silvin, Zhong Chen, Carter Van Waes. Linkage of NF-κB pathway and mitosis-related molecules using integrated RNAi screening and transcriptomic analysis of head and neck squamous cell carcinoma [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 605.

NF-κB Over-Activation Portends Improved Outcomes in HPV-associated Head and Neck Cancer.

Noncanonical HPV carcinogenesis drives radiosensitization of head and neck tumors

Defective TRAF3 Modulates Alternative NF-kB Signaling and Cytokine Expression to Promote Cancer Cell Survival in HPV Positive Head and Neck Cancer (TUM10P.1049)

Genetic Alterations in TRAF3 and CYLD That Regulate Nuclear Factor Κb and Interferon Signaling Define Head and Neck Cancer Subsets Harboring Human Papillomavirus

Abstract 3170: Alternative NF-κB pathway activation enhanced by deficient TRAF3 in human papillomavirus (HPV)-associated head and neck cancer

Attenuated TRAF3 Fosters Activation of Alternative NF-κB and Reduced Expression of Antiviral Interferon, TP53, and RB to Promote HPV-Positive Head and Neck Cancers.

Mutational profiles of head and neck squamous cell carcinomas based upon human papillomavirus status in the Veterans Affairs National Precision Oncology Program

NCBP2 and TFRC are novel prognostic biomarkers in oral squamous cell carcinoma

Abstract 1298: The role of nuclear factor kappa B in survival of human papillomavirus-positive head and neck cancer cell lines.

Identification of lncRNA Signature of Tumor-Infiltrating T Lymphocytes With Potential Implications for Prognosis and Chemotherapy of Head and Neck Squamous Cell Carcinoma

Supplementary Information from Attenuated TRAF3 Fosters Activation of Alternative NF-κB and Reduced Expression of Antiviral Interferon, TP53, and RB to Promote HPV-Positive Head and Neck Cancers

Correlation of Specific Genetic Aberrations and Signaling Pathways with T-cell Inflamed Phenotype (TCIP) in Head and Neck Cancer and As Novel Candidate Biomarkers for Checkpoint Blockade Therapy.

Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas

A Novel Nuclear Factor-Kappab Gene Signature is Differentially Expressed in Head and Neck Squamous Cell Carcinomas in Association with TP53 Status.

Data from Functional RNAi Screening Identifies G2/M and Kinetochore Components As Modulators of TNFα/NF-κB Prosurvival Signaling in Head and Neck Squamous Cell Carcinoma

Abstract 605: Linkage of NF-κB pathway and mitosis-related molecules using integrated RNAi screening and transcriptomic analysis of head and neck squamous cell carcinoma

Traf3 Serves As A Tumor Suppressor In Hpv-Associated Head And Neck Squamous Cell Carcinomas

Supplemental Table 2 from Attenuated TRAF3 Fosters Activation of Alternative NF-κB and Reduced Expression of Antiviral Interferon, TP53, and RB to Promote HPV-Positive Head and Neck Cancers

Abstract 4498: Prognostic Significance of Nuclear Factor Kappa B Expression in Human Papillomavirus-Associated Oropharyngeal Cancer

Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma

Dysregulation of base excision repair factors associated with low tumor immunogenicity in head and neck cancer: implication for immunotherapy